3M Company (MMM) is in the news today because of an investor meeting. Here's one bullet point from TheFly. The gathering brought my mind back to the stock. How is it looking these days?

Well, it's pulled back from the 52-week high. At the time of this writing, shares were fetching a price of $88.68. The top point for the year is currently set at $94.16; the low point is $67.98, so thankfully we're nowhere near that depressing level. (Could the bearishness become so bad that we eventually get close to that price? Don't even think it!).

The shares of 3M Company (MMM), first discussed here on April 20, 2009, at a price of $51.97, have meandered during the past three months, but I still like the business model at this stage. Here's why.

3M's 2011 revenue will likely increase 12% to 14%, after a 15% rise in 2010, propelled higher by strength in all business lines: industrial, health care, display and graphics, consumer/office, electronics/communications, and safety/security. Further, 3M's demonstrated innovation prowess and commitment to research/development make it a formidable industrial giant.

Analyst Upgrades

• Diamond Offshore (DO) to conviction buy from sell and Baker Hughes (BHI) to buy from neutral at Goldman.
• Frontier Communications (FTR) to outperform from market perform at Wells Fargo.
• Syntel (SYNT) to outperform from market perform at Wells Fargo, to buy from hold at Deutsche Bank and to buy from neutral at Janney Capital.
• Kulicke & Soffa (KLIC) and Fiserv (FISV) to outperform from perform at Oppenheimer.
• 3M (MMM) to neutral from underweight and Tyco (TYC) to overweight from neutral at JPMorgan.
• Collective Brands (PSS) and Nordstrom (JWN) to overweight from equal weight, as well as Foot Locker (FL) to equal weight from underweight, at Morgan Stanley.
• Amazon.com (AMZN) to buy from hold at Lazard Capital.
• Yamana Gold (AUY) to outperform from neutral at Credit Suisse.

Beckman Coulter (BEC), a top medical diagnostic instruments company, has been public over 20 years. But it looks like its days of independence may soon be over. According to a report in the Wall Street Journal, Beckman is in the process of selling itself. So far in today's trading, the shares are up 27% to $72.57, with the market cap at about $5 billion.

Beckman's products span many categories like biomedical testing and lab automation. The installed base is roughly 200,000. In fact, a large portion of the revenues come from recurring sources (such as refilling supplies for the machines). In other words, Beckman has sturdy cash flow stream.

Analyst Upgrades

• Red Hat (RHT) and American Public (APEI) to outperform from sector perform at RBC Capital.
• KBR (KBR) and Foster Wheeler (FWLT) to buy from neutral at Goldman.
• Bio-Rad (BIO) to outperform from market perform at Leerink.
• Oceaneering (OII) to outperform from neutral at Credit Suisse.
• ASM International (ASMI) and Avid Technology (AVID) to overweight from neutral at JPMorgan.
• Dominion Resources (D) to equal weight from underweight at Morgan Stanley.
• Nationwide Health Properties (NHP) to buy from hold at Jefferies.
• Vivus (VVUS) to buy from underperform at BofA/Merrill.
• Intersil (ISIL) to buy from hold at Canaccord.

The earnings crunch continues this week, and analysts surveyed by Thomson Reuters are anticipating lots of strong quarterly reports.

For example, year-over-year earnings growth from big oil Chevron (CVX), ConocoPhillips (COP), ExxonMobil (XOM) and Royal Dutch Shell (RDS.A) are expected to be in double digits. The same is true of many other energy and mining concerns reporting this week: Allegheny Technologies (ATI), Alliant Energy (LNT), Arch Coal (ACI), Cliffs Natural Resources (CLF), CMS Energy (CMS), CONSOL Energy (CNX), DPL (DPL), Hess Corp. (HES), Minerals Technologies (MTX), Pioneer Natural Resources (PXD), PPL Corp. (PPL), Southwestern Energy (SWN), Total (TOT), Whiting Petroleum (WLL), Williams Companies (WMB) and Wisconsin Energy (WEC).

Analyst Upgrades

• Citigroup assumed coverage of Illinois Tool Works (ITW) and upgraded shares to buy from hold with a $52 price target. Citi cites valuation and the company's successful execution for the rating change.
• UBS upgraded Rowan Companies (RDC) to buy from neutral based on better-than-expected dayrates in the high specification jack-up market. The firm raised its price target to $42 from $28.
• UBS also upgraded NetLogic (NETL) to buy from neutral and keeps a $33.50 target on the stock. The firm upgraded shares based on valuation and solid long-term outlook.
• AvalonBay (AVB) and BRE Properties (BRE) were upgraded to neutral from underperform at Macquarie.
• Covance (CVD) was upgraded to equal weight from underweight at Morgan Stanley.
• Reynolds American (RAI) was upgraded to neutral from underperform at BofA/Merrill.

M & A. That's mergers and acquisitions. They're all over the financial pages. Intel (INTC) is buying Infineon's wireless division for $1.4 billion so the chip manufacturer can diversify beyond computers. HP (HPQ) or Dell (DELL) will end up with 3PAR, a cloud-computing company, at a cost of $2 billion or more. Carl Icahn, the billionaire financier, is making a hostile tender bid for Lions Gate (LGF), the film and television producer. 3M (MMM) is buying Attenti Holdings, an Israeli maker of remote monitoring technology used to track people, for $230 million. Exelon (EXC) is picking up a division of Deere (DE), a renewable energy unit, for about $900 million so it can enter the wind-power segment. Sanofi-Aventis (SNYNF) is trying to buy Genzyme (GENZ) but the board won't accept the bid of $18.5 billion. The board is open to better numbers. There are many more.

Is all this good for investors? Or is there some bad in there?

"For much of the market's rally since March 2009, the best-performing stocks were those that tilted toward the risky side. That is about to change," says Chuck Carlson.

The editor of The DRIP Investor explains, "Quality stocks -- larger companies with consistent track records, strong finances, industry leadership positions, and stable and growing dividends -- should lead the market going forward.

"Quality stocks now offer good relative value versus more aggressive stocks, and I suspect investors will be more focused on a value over the next 12 to 24 months.